Benzoyl Peroxide; Tretinoin Patent Expiration

Benzoyl Peroxide; Tretinoin is Used for treating acne vulgaris in adults and pediatric patients 9 years of age and older. It was first introduced by Galderma Laboratories Lp in its drug Twyneo on Jul 26, 2021.


Benzoyl Peroxide; Tretinoin Patents

Given below is the list of patents protecting Benzoyl Peroxide; Tretinoin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Twyneo US10420743 Methods and compositions for the treatment of acne Jul 12, 2038 Galderma Labs Lp
Twyneo US12053546 Stabilized topical formulations containing core-shell microcapsules Jun 29, 2032 Galderma Labs Lp
Twyneo US10653899 Core stabilized microcapsules, method of their preparation and uses thereof Dec 30, 2030 Galderma Labs Lp
Twyneo US11071878 Core stabilized microcapsules, method of their preparation and uses thereof Dec 30, 2030 Galderma Labs Lp
Twyneo US9868103 Metal oxide coating of water insoluble ingredients Aug 08, 2028 Galderma Labs Lp
Twyneo US8617580 Compositions for topical application comprising a peroxide and retinoid Feb 03, 2028 Galderma Labs Lp



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Benzoyl Peroxide; Tretinoin's patents.

Given below is the list recent legal activities going on the following patents of Benzoyl Peroxide; Tretinoin.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 20 Nov, 2023 US10653899
Payment of Maintenance Fee, 4th Year, Large Entity 24 Mar, 2023 US10420743
Mail O.P. Petition Decision 23 Mar, 2023 US8617580
Email Notification 23 Mar, 2023 US8617580
Mail-Record Petition Decision of Granted to Make Entity Status large 21 Mar, 2023 US8617580
Record Petition Decision of Granted to Make Entity Status large 20 Mar, 2023 US8617580
O.P. Petition Decision 16 Mar, 2023 US8617580
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jan, 2023 US10420743
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 28 Dec, 2022 US11071878
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 28 Dec, 2022 US10653899


Benzoyl Peroxide; Tretinoin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List